{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:03:36Z","timestamp":1790633016963,"version":"4.1.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,5,10]],"date-time":"2019-05-10T00:00:00Z","timestamp":1557446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,5,10]],"date-time":"2019-05-10T00:00:00Z","timestamp":1557446400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001321","name":"National Research Foundation","doi-asserted-by":"publisher","award":["2016R1A6A3A11933839"],"award-info":[{"award-number":["2016R1A6A3A11933839"]}],"id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001321","name":"National Research Foundation","doi-asserted-by":"publisher","award":["2015R1DA1A01057022"],"award-info":[{"award-number":["2015R1DA1A01057022"]}],"id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005006","name":"Asan Institute for Life Sciences, Asan Medical Center","doi-asserted-by":"publisher","award":["2017-738"],"award-info":[{"award-number":["2017-738"]}],"id":[{"id":"10.13039\/501100005006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005006","name":"Asan Institute for Life Sciences, Asan Medical Center","doi-asserted-by":"publisher","award":["2017-563"],"award-info":[{"award-number":["2017-563"]}],"id":[{"id":"10.13039\/501100005006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005006","name":"Asan Institute for Life Sciences, Asan Medical Center","doi-asserted-by":"publisher","award":["2017-738"],"award-info":[{"award-number":["2017-738"]}],"id":[{"id":"10.13039\/501100005006","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Mantle cell lymphoma (MCL) is typically an aggressive and rare form of non-Hodgkin lymphoma (NHL) with a poor prognosis despite recent advances in immunochemotherapy and targeted therapeutics against NHL. New therapeutic agents are needed for MCL. In this study, we generated a potent inhibitor of cyclin-dependent kinase 7 (CDK7), designated QS1189, and confirmed its anti-cancer effects towards MCL and other lymphomas. QS1189 was highly selective for CDK7 and showed potent anticancer effects in MCL compared to other targeted therapeutic agents, such as ibrutinib and venetoclax. Consistent with a conventional CDK7 inhibitor, QS1189 treatment significantly decreased phosphorylation of the carboxyl-terminal domain of RNA polymerase II and transcription-associated genes. QS1189 induced cell cycle arrest at the G2\/M phase and apoptosis. Interestingly, QS1189 overcame the acquired resistance to venetoclax, which is mediated by Bcl-xL. Similarly, QS1189 showed potent tumour cell growth inhibition of various lymphomas. Thus, CDK7 might be a suitable therapeutic target for inhibiting lymphoma, and QS1189 is a promising therapeutic option for various lymphomas and cells with acquired resistance to targeted therapy.<\/jats:p>","DOI":"10.1038\/s41598-019-43760-z","type":"journal-article","created":{"date-parts":[[2019,5,10]],"date-time":"2019-05-10T10:04:37Z","timestamp":1557482677000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Efficacy of the novel CDK7 inhibitor QS1189 in mantle cell lymphoma"],"prefix":"10.1038","volume":"9","author":[{"given":"Yun Jung","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Ha","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dok Hyun","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheolwon","family":"Suh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Min","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Cheol","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Yong","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Kyung","family":"Rho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,10]]},"reference":[{"issue":"Suppl 3","key":"43760_CR1","doi-asserted-by":"publisher","first-page":"iii83","DOI":"10.1093\/annonc\/mdu264","volume":"25","author":"M Dreyling","year":"2014","unstructured":"Dreyling, M. et al. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 25(Suppl 3), iii83\u201392, https:\/\/doi.org\/10.1093\/annonc\/mdu264 (2014).","journal-title":"Ann Oncol"},{"key":"43760_CR2","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1200\/JCO.2008.16.8435","volume":"27","author":"A Herrmann","year":"2009","unstructured":"Herrmann, A. et al. Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol 27, 511\u2013518, https:\/\/doi.org\/10.1200\/JCO.2008.16.8435 (2009).","journal-title":"J Clin Oncol"},{"key":"43760_CR3","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1056\/NEJMoa1412096","volume":"372","author":"T Robak","year":"2015","unstructured":"Robak, T. et al. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. N Engl J Med 372, 944\u2013953, https:\/\/doi.org\/10.1056\/NEJMoa1412096 (2015).","journal-title":"N Engl J Med"},{"key":"43760_CR4","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1111\/j.1365-2141.2010.08228.x","volume":"150","author":"JE Romaguera","year":"2010","unstructured":"Romaguera, J. E. et al. Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate\/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol 150, 200\u2013208, https:\/\/doi.org\/10.1111\/j.1365-2141.2010.08228.x (2010).","journal-title":"Br J Haematol"},{"key":"43760_CR5","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1200\/JCO.2010.28.9777","volume":"29","author":"C Tarella","year":"2011","unstructured":"Tarella, C. et al. Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphoma. J Clin Oncol 29, 814\u2013824, https:\/\/doi.org\/10.1200\/JCO.2010.28.9777 (2011).","journal-title":"J Clin Oncol"},{"key":"43760_CR6","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/S0140-6736(15)00667-4","volume":"387","author":"M Dreyling","year":"2016","unstructured":"Dreyling, M. et al. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet 387, 770\u2013778, https:\/\/doi.org\/10.1016\/S0140-6736(15)00667-4 (2016).","journal-title":"Lancet"},{"key":"43760_CR7","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1056\/NEJMoa1306220","volume":"369","author":"ML Wang","year":"2013","unstructured":"Wang, M. L. et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 369, 507\u2013516, https:\/\/doi.org\/10.1056\/NEJMoa1306220 (2013).","journal-title":"N Engl J Med"},{"key":"43760_CR8","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","volume":"35","author":"MS Davids","year":"2017","unstructured":"Davids, M. S. et al. Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma. J Clin Oncol 35, 826\u2013833, https:\/\/doi.org\/10.1200\/JCO.2016.70.4320 (2017).","journal-title":"J Clin Oncol"},{"key":"43760_CR9","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1146\/annurev.cellbio.13.1.261","volume":"13","author":"DO Morgan","year":"1997","unstructured":"Morgan, D. O. Cyclin-dependent kinases: engines, clocks, and microprocessors. Annu Rev Cell Dev Biol 13, 261\u2013291, https:\/\/doi.org\/10.1146\/annurev.cellbio.13.1.261 (1997).","journal-title":"Annu Rev Cell Dev Biol"},{"key":"43760_CR10","doi-asserted-by":"publisher","first-page":"146","DOI":"10.4161\/trns.25146","volume":"4","author":"M Sanso","year":"2013","unstructured":"Sanso, M. & Fisher, R. P. Pause, play, repeat: CDKs push RNAP II\u2019s buttons. Transcription 4, 146\u2013152 (2013).","journal-title":"Transcription"},{"key":"43760_CR11","doi-asserted-by":"publisher","first-page":"5171","DOI":"10.1242\/jcs.02718","volume":"118","author":"RP Fisher","year":"2005","unstructured":"Fisher, R. P. Secrets of a double agent: CDK7 in cell-cycle control and transcription. J Cell Sci 118, 5171\u20135180, https:\/\/doi.org\/10.1242\/jcs.02718 (2005).","journal-title":"J Cell Sci"},{"key":"43760_CR12","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1177\/1947601912473308","volume":"3","author":"RP Fisher","year":"2012","unstructured":"Fisher, R. P. The CDK Network: Linking Cycles of Cell Division and Gene Expression. Genes Cancer 3, 731\u2013738, https:\/\/doi.org\/10.1177\/1947601912473308 (2012).","journal-title":"Genes Cancer"},{"key":"43760_CR13","doi-asserted-by":"publisher","first-page":"5923","DOI":"10.1128\/MCB.17.10.5923","volume":"17","author":"H Lu","year":"1997","unstructured":"Lu, H., Fisher, R. P., Bailey, P. & Levine, A. J. The CDK7-cycH-p36 complex of transcription factor IIH phosphorylates p53, enhancing its sequence-specific DNA binding activity in vitro. Mol Cell Biol 17, 5923\u20135934 (1997).","journal-title":"Mol Cell Biol"},{"key":"43760_CR14","doi-asserted-by":"publisher","first-page":"21896","DOI":"10.1074\/jbc.M001985200","volume":"275","author":"J Bastien","year":"2000","unstructured":"Bastien, J. et al. TFIIH interacts with the retinoic acid receptor gamma and phosphorylates its AF-1-activating domain through cdk7. J Biol Chem 275, 21896\u201321904, https:\/\/doi.org\/10.1074\/jbc.M001985200 (2000).","journal-title":"J Biol Chem"},{"key":"43760_CR15","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/S0092-8674(00)80317-7","volume":"90","author":"C Rochette-Egly","year":"1997","unstructured":"Rochette-Egly, C., Adam, S., Rossignol, M., Egly, J. M. & Chambon, P. Stimulation of RAR alpha activation function AF-1 through binding to the general transcription factor TFIIH and phosphorylation by CDK7. Cell 90, 97\u2013107 (1997).","journal-title":"Cell"},{"key":"43760_CR16","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1038\/emboj.2010.337","volume":"30","author":"P Chymkowitch","year":"2011","unstructured":"Chymkowitch, P., Le May, N., Charneau, P., Compe, E. & Egly, J. M. The phosphorylation of the androgen receptor by TFIIH directs the ubiquitin\/proteasome process. EMBO J 30, 468\u2013479, https:\/\/doi.org\/10.1038\/emboj.2010.337 (2011).","journal-title":"EMBO J"},{"key":"43760_CR17","doi-asserted-by":"publisher","first-page":"9308","DOI":"10.1074\/jbc.275.13.9308","volume":"275","author":"DK Lee","year":"2000","unstructured":"Lee, D. K., Duan, H. O. & Chang, C. From androgen receptor to the general transcription factor TFIIH. Identification of cdk activating kinase (CAK) as an androgen receptor NH(2)-terminal associated coactivator. J Biol Chem 275, 9308\u20139313 (2000).","journal-title":"J Biol Chem"},{"key":"43760_CR18","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S1097-2765(05)00004-3","volume":"6","author":"D Chen","year":"2000","unstructured":"Chen, D. et al. Activation of estrogen receptor alpha by S118 phosphorylation involves a ligand-dependent interaction with TFIIH and participation of CDK7. Mol Cell 6, 127\u2013137 (2000).","journal-title":"Mol Cell"},{"key":"43760_CR19","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/j.cell.2014.10.024","volume":"159","author":"E Chipumuro","year":"2014","unstructured":"Chipumuro, E. et al. CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer. Cell 159, 1126\u20131139, https:\/\/doi.org\/10.1016\/j.cell.2014.10.024 (2014).","journal-title":"Cell"},{"key":"43760_CR20","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/j.ccell.2014.10.019","volume":"26","author":"CL Christensen","year":"2014","unstructured":"Christensen, C. L. et al. Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor. Cancer Cell 26, 909\u2013922, https:\/\/doi.org\/10.1016\/j.ccell.2014.10.019 (2014).","journal-title":"Cancer Cell"},{"key":"43760_CR21","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/nature13393","volume":"511","author":"N Kwiatkowski","year":"2014","unstructured":"Kwiatkowski, N. et al. Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. Nature 511, 616\u2013620, https:\/\/doi.org\/10.1038\/nature13393 (2014).","journal-title":"Nature"},{"key":"43760_CR22","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1158\/1535-7163.MCT-17-0078","volume":"16","author":"Z Zhang","year":"2017","unstructured":"Zhang, Z. et al. Preclinical Efficacy and Molecular Mechanism of Targeting CDK7-Dependent Transcriptional Addiction in Ovarian Cancer. Mol Cancer Ther 16, 1739\u20131750, https:\/\/doi.org\/10.1158\/1535-7163.MCT-17-0078 (2017).","journal-title":"Mol Cancer Ther"},{"key":"43760_CR23","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1136\/gutjnl-2016-311818","volume":"66","author":"YY Jiang","year":"2017","unstructured":"Jiang, Y. Y. et al. Targeting super-enhancer-associated oncogenes in oesophageal squamous cell carcinoma. Gut 66, 1358\u20131368, https:\/\/doi.org\/10.1136\/gutjnl-2016-311818 (2017).","journal-title":"Gut"},{"key":"43760_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14290","volume":"8","author":"F Cayrol","year":"2017","unstructured":"Cayrol, F. et al. THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors. Nat Commun 8, 14290, https:\/\/doi.org\/10.1038\/ncomms14290 (2017).","journal-title":"Nat Commun"},{"key":"43760_CR25","unstructured":"Clark, K. et al. CT7001, a Novel Orally Bio-Available CDK7 Inhibitor, Is Highly Active in in-Vitro and in-Vivo Models of AML. Blood 130 (2017)."},{"key":"43760_CR26","unstructured":"Hodgson, G. et al. Sy-1365, a Potent and Selective CDK7 Inhibitor, Exhibits Anti-Tumor Activity in Preclinical Models of Hematologic Malignancies, and Demonstrates Interactions with the BCL-XL\/BCL2 Mitochondrial Apoptosis Signaling Pathway in Leukemia. Blood 130 (2017)."},{"key":"43760_CR27","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1128\/AAC.04534-14","volume":"59","author":"C Hutterer","year":"2015","unstructured":"Hutterer, C. et al. A novel CDK7 inhibitor of the Pyrazolotriazine class exerts broad-spectrum antiviral activity at nanomolar concentrations. Antimicrob Agents Chemother 59, 2062\u20132071, https:\/\/doi.org\/10.1128\/AAC.04534-14 (2015).","journal-title":"Antimicrob Agents Chemother"},{"key":"43760_CR28","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1158\/1535-7163.Mct-16-0847","volume":"17","author":"H Patel","year":"2018","unstructured":"Patel, H. et al. ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment. Molecular Cancer Therapeutics 17, 1156\u20131166, https:\/\/doi.org\/10.1158\/1535-7163.Mct-16-0847 (2018).","journal-title":"Molecular Cancer Therapeutics"},{"key":"43760_CR29","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.molcel.2009.04.016","volume":"34","author":"MS Akhtar","year":"2009","unstructured":"Akhtar, M. S. et al. TFIIH kinase places bivalent marks on the carboxy-terminal domain of RNA polymerase II. Mol Cell 34, 387\u2013393, https:\/\/doi.org\/10.1016\/j.molcel.2009.04.016 (2009).","journal-title":"Mol Cell"},{"key":"43760_CR30","doi-asserted-by":"publisher","first-page":"5455","DOI":"10.1128\/MCB.00637-09","volume":"29","author":"K Glover-Cutter","year":"2009","unstructured":"Glover-Cutter, K. et al. TFIIH-associated Cdk7 kinase functions in phosphorylation of C-terminal domain Ser7 residues, promoter-proximal pausing, and termination by RNA polymerase II. Mol Cell Biol 29, 5455\u20135464, https:\/\/doi.org\/10.1128\/MCB.00637-09 (2009).","journal-title":"Mol Cell Biol"},{"key":"43760_CR31","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/0092-8674(94)90039-6","volume":"79","author":"R Roy","year":"1994","unstructured":"Roy, R. et al. The MO15 cell cycle kinase is associated with the TFIIH transcription-DNA repair factor. Cell 79, 1093\u20131101 (1994).","journal-title":"Cell"},{"key":"43760_CR32","unstructured":"Huang, S. J. et al. Resistance Mechanisms Underlying Venetoclax Resistance in Mantle Cell Lymphoma. Blood 130 (2017)."},{"key":"43760_CR33","doi-asserted-by":"publisher","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","volume":"112","author":"CH Geisler","year":"2008","unstructured":"Geisler, C. H. et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 112, 2687\u20132693, https:\/\/doi.org\/10.1182\/blood-2008-03-147025 (2008).","journal-title":"Blood"},{"key":"43760_CR34","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/j.1365-2141.2011.08958.x","volume":"156","author":"F Merli","year":"2012","unstructured":"Merli, F. et al. Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi. Br J Haematol 156, 346\u2013353, https:\/\/doi.org\/10.1111\/j.1365-2141.2011.08958.x (2012).","journal-title":"Br J Haematol"},{"key":"43760_CR35","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","volume":"123","author":"IW Flinn","year":"2014","unstructured":"Flinn, I. W. et al. Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood 123, 2944\u20132952, https:\/\/doi.org\/10.1182\/blood-2013-11-531327 (2014).","journal-title":"Blood"},{"key":"43760_CR36","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1056\/NEJMoa1200920","volume":"367","author":"HC Kluin-Nelemans","year":"2012","unstructured":"Kluin-Nelemans, H. C. et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med 367, 520\u2013531, https:\/\/doi.org\/10.1056\/NEJMoa1200920 (2012).","journal-title":"N Engl J Med"},{"key":"43760_CR37","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","volume":"381","author":"MJ Rummel","year":"2013","unstructured":"Rummel, M. J. et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 381, 1203\u20131210, https:\/\/doi.org\/10.1016\/S0140-6736(12)61763-2 (2013).","journal-title":"Lancet"},{"key":"43760_CR38","doi-asserted-by":"publisher","first-page":"3675","DOI":"10.1128\/MCB.00595-14","volume":"34","author":"TW Kelso","year":"2014","unstructured":"Kelso, T. W. et al. Cyclin-dependent kinase 7 controls mRNA synthesis by affecting stability of preinitiation complexes, leading to altered gene expression, cell cycle progression, and survival of tumor cells. Mol Cell Biol 34, 3675\u20133688, https:\/\/doi.org\/10.1128\/MCB.00595-14 (2014).","journal-title":"Mol Cell Biol"},{"key":"43760_CR39","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.cell.2015.08.063","volume":"163","author":"Y Wang","year":"2015","unstructured":"Wang, Y. et al. CDK7-dependent transcriptional addiction in triple-negative breast cancer. Cell 163, 174\u2013186, https:\/\/doi.org\/10.1016\/j.cell.2015.08.063 (2015).","journal-title":"Cell"},{"key":"43760_CR40","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/j.humpath.2004.04.018","volume":"35","author":"JH Cho-Vega","year":"2004","unstructured":"Cho-Vega, J. H. et al. MCL-1 expression in B-cell non-Hodgkin\u2019s lymphomas. Hum Pathol 35, 1095\u20131100 (2004).","journal-title":"Hum Pathol"},{"key":"43760_CR41","doi-asserted-by":"publisher","first-page":"3884","DOI":"10.1182\/blood-2013-05-498329","volume":"122","author":"G Ott","year":"2013","unstructured":"Ott, G., Rosenwald, A. & Campo, E. Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification. Blood 122, 3884\u20133891, https:\/\/doi.org\/10.1182\/blood-2013-05-498329 (2013).","journal-title":"Blood"},{"key":"43760_CR42","doi-asserted-by":"publisher","first-page":"4599","DOI":"10.1182\/blood-2006-08-039859","volume":"109","author":"A Wiestner","year":"2007","unstructured":"Wiestner, A. et al. Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival. Blood 109, 4599\u20134606, https:\/\/doi.org\/10.1182\/blood-2006-08-039859 (2007).","journal-title":"Blood"},{"key":"43760_CR43","first-page":"2615","volume":"59","author":"J Adams","year":"1999","unstructured":"Adams, J. et al. Proteasome inhibitors: A novel class of potent and effective antitumor agents. Cancer Research 59, 2615\u20132622 (1999).","journal-title":"Cancer Research"},{"issue":"11","key":"43760_CR44","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.1080\/10428194.2017.1421760","volume":"59","author":"Vijay Ramakrishnan","year":"2018","unstructured":"Ramakrishnan, V. & Kumar, S. PI3K\/AKT\/mTOR pathway in multiple myeloma: from basic biology to clinical promise. Leuk Lymphoma, 1\u201311, https:\/\/doi.org\/10.1080\/10428194.2017.1421760 (2018).","journal-title":"Leukemia & Lymphoma"},{"key":"43760_CR45","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1080\/13543784.2018.1482273","volume":"27","author":"K Valla","year":"2018","unstructured":"Valla, K., Flowers, C. R. & Koff, J. L. Targeting the B cell receptor pathway in non-Hodgkin lymphoma. Expert Opin Investig Drugs 27, 513\u2013522, https:\/\/doi.org\/10.1080\/13543784.2018.1482273 (2018).","journal-title":"Expert Opin Investig Drugs"},{"key":"43760_CR46","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1200\/JCO.2007.14.5367","volume":"26","author":"AA Chanan-Khan","year":"2008","unstructured":"Chanan-Khan, A. A. & Cheson, B. D. Lenalidomide for the treatment of B-cell malignancies. J Clin Oncol 26, 1544\u20131552, https:\/\/doi.org\/10.1200\/JCO.2007.14.5367 (2008).","journal-title":"J Clin Oncol"},{"key":"43760_CR47","doi-asserted-by":"publisher","first-page":"4111","DOI":"10.1182\/blood-2014-03-560284","volume":"123","author":"V Fresquet","year":"2014","unstructured":"Fresquet, V., Rieger, M., Carolis, C., Garcia-Barchino, M. J. & Martinez-Climent, J. A. Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma. Blood 123, 4111\u20134119, https:\/\/doi.org\/10.1182\/blood-2014-03-560284 (2014).","journal-title":"Blood"},{"issue":"1","key":"43760_CR48","doi-asserted-by":"publisher","first-page":"e1593","DOI":"10.1038\/cddis.2014.525","volume":"6","author":"G S Choudhary","year":"2015","unstructured":"Choudhary, G. S. et al. MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K\/AKT\/mTOR activation in lymphoid malignancies. Cell Death Dis 6, https:\/\/doi.org\/10.1038\/cddis.2014.525 (2015).","journal-title":"Cell Death & Disease"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-43760-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-43760-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-43760-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T09:30:18Z","timestamp":1671269418000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-43760-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,10]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["43760"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-43760-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,10]]},"assertion":[{"value":"20 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"7193"}}